Drug intelligence / Profile preview

NPD-1902

Development stage
Preclinical
Lead developer
Nogra Pharma Ltd.
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

NPD-1902 is an oligonucleotide therapeutic under development by Nogra Pharma for the treatment of immune-inflammatory-mediated diseases, with a specific focus on Crohn's disease. Part of the company's proprietary oligonucleotide platform, NPD-1902 is designed to modulate disease-associated protein expression by down-regulating target proteins involved in inflammatory pathways. While the specific molecular target remains undisclosed, the candidate is currently in the formulation development stage of preclinical research, following the company's strategy of utilizing oligonucleotide-based modalities to address chronic inflammatory conditions.

Beyond the preview

Go deeper on NPD-1902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPD-1902.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call